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The IB Function of NF-B2 p100 Controls
Stimulated Osteoclastogenesis
Deborah Veis Novack,1,2 Li Yin,1 Amanda Hagen-Stapleton,1 Robert D. Schreiber,1
David V. Goeddel,3 F. Patrick Ross,1 and Steven L. Teitelbaum1
1Department

of Pathology and Immunology, and 2Department of Medicine,Washington University School of
Medicine, St. Louis, MO 63110
3Tularik, Inc., South San Francisco, CA 94080

The prototranscription factor p100 represents an intersection of the NF-B and IB families,
potentially serving as both the precursor for the active NF-B subunit p52 and as an IB capable
of retaining NF-B in the cytoplasm. NF-B–inducing kinase (NIK) controls processing of
p100 to generate p52, and thus NIK-deficient mice can be used to examine the biological effects
of a failure in such processing. We demonstrate that treatment of wild-type osteoclast precursors
with the osteoclastogenic cytokine receptor activator of NF-B ligand (RANKL) increases
both expression of p100 and its conversion to p52, resulting in unchanged net levels of p100.
In the absence of NIK, p100 expression is increased by RANKL, but its conversion to p52 is
blocked, leading to cytosolic accumulation of p100, which, acting as an IB protein, binds
NF-B complexes and prevents their nuclear translocation. High levels of unprocessed p100 in
osteoclast precursors from NIK/ mice or a nonprocessable form of the protein in wild-type
cells impair RANKL-mediated osteoclastogenesis. Conversely, p100-deficient osteoclast precursors show enhanced sensitivity to RANKL. These data demonstrate a novel, biologically
relevant means of regulating NF-B signaling, with upstream control and kinetics distinct from
the classical IB pathway.
Key words: mice knockout • bone remodeling/physiology • MAP kinase kinase kinases •
cultured cells/physiology • murine RANKL

Introduction
Osteoclasts (OCs) are multinucleated cells derived from
mononuclear myeloid bone marrow progenitors that express
receptor activator of NF-B (RANK), the receptor for the
key osteoclastogenic cytokine RANK ligand (RANKL)
(1). Interaction of RANK with RANKL in the presence of
macrophage CSF (M-CSF) promotes OC differentiation.
Thus, deletion of the RANK, RANKL, or M-CSF genes
leads to an absence of OCs, causing osteopetrosis. Like
other members of the TNF receptor superfamily, RANK
potently activates the NF-B pathway.
In the canonical NF-B pathway (for reviews see reference 2, 3), ligation of a transmembrane receptor such as
RANK activates the IB kinase (IKK) complex, which
phosphorylates NF-B–associated IB, leading to its ubiquitination and proteosomal degradation. These events release
Address correspondence to Deborah Veis Novack, Washington University
School of Medicine, 660 S. Euclid Ave., Box 8301, St. Louis, MO
63110. Phone: (314) 454-8472; Fax: (314) 454-5047;
email: novack@wustl.edu
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NF-B subunits in the cytosol, allowing them to travel to
the nucleus where they enhance transcription of target
genes. In mammals, the NF-B family has five members:
RelA (p65), RelB, c-Rel, NF-B1, and NF-B2. RelA,
RelB, and c-Rel are synthesized as mature proteins, each
bearing a transcriptional transactivation domain and a
DNA-binding Rel homology domain. In contrast, the active
forms of NF-B1 and NF-B2, p50 and p52, are derived
from the full-length products of the nfkb1 and nfkb2 genes,
p105 and p100, respectively. The generation of the transcriptionally active subunits p50 and p52 is dependent on
phosphorylation of their precursors followed by ubiquitination and partial proteosomal degradation of their COOH
Abbreviations used in this paper: CTR, calcitonin receptor; EMSA, electrophoretic mobility shift assay; IKK, IB kinase; M, bone marrow–derived
macrophages; M-CSF, macrophage CSF; MMP9, matrix metalloproteinase
9; NIK, NF-B–inducing kinase; OC, osteoclast; RANK, receptor activator of NF-B ligand; RANKL, RANK ligand; TRAP, tartrate-resistant
acid phosphatase.
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termini (4, 5). The NH2-terminal Rel homology domain of
p50 or p52, when cleaved from the COOH terminus, can
form active NF-B dimers with RelA, RelB, or c-Rel.
The COOH-terminal portions of p105 and p100, before
processing to p50 and p52, contain IB-like ankyrin repeats. Thus, similar to IB, p105 and p100 are capable of
retaining proteins with a Rel domain in the cytosol (6, 7).
p105 is ubiquitously expressed, and its conversion to p50
appears to be largely constitutive, with only modest increases in levels of p50 in response to NF-B activation (2).
In contrast, p100 is expressed predominantly in lymphoid
organs (8), and its processing is tightly controlled by a
kinase cascade. NF-B–inducing kinase (NIK) activates
IKK (a subunit of the IKK complex), which phosphorylates p100, targeting it for processing to p52 (9, 10).
The importance of the NIK/IKK/p100/p52 pathway
has been highlighted by several mouse models. The nfkb2
knockout mouse, which lacks both p100 and p52, exhibits
abnormal B cell differentiation and function (11, 12). Radiation chimeras bearing IKK/ bone marrow or mice expressing nonactivatable IKK have decreased p52 levels and
similar defects in B cell maturation (10). Alymphoplasia (aly/
aly) mice (13), which carry a mutation in the IKK interaction domain of NIK (14, 15), also have diminished p52 levels (9, 16) and defective B cell maturation (16). Finally, animals lacking the COOH-terminal IB-like domain of
NFB2, and which thus express unregulated p52, have increased lymphocyte proliferation and gastric mucosal hyperplasia (17). In sum, these models demonstrate that regulated
expression of the active NF-B subunit p52, via NIK- and
IKK-mediated processing of p100, is biologically relevant.
Despite these findings, the importance of the putative inhibitory effect of unprocessed p100 on global NF-B activation, via its IB activity, has not been established. In this
study, we have used the NIK-deficient mouse (18) to examine the effects of a lack of p100 processing on OC differentiation and NF-B signaling. Previous studies of the
NIK/IKK/p100 pathway in a physiological context have
only been performed in the B cell lineage, which is dependent on p52 for full maturation (11, 12). The nfkb2 knockout mouse, which lacks both p100 and p52, has normal
basal osteoclastogenesis in vivo (19), indicating that, in
contrast to its role in B cell development, p52 itself is dispensable for OC differentiation. The fact that the NIK/
mouse fails to process p100 to p52 positions us to examine
the potential role of p100 in osteoclastogenesis, in the absence of a requirement for p52. Our studies show that
when p100 levels are increased, as in NIK-deficient OC
precursors, RANKL-stimulated osteoclastogenesis is impaired. Conversely, we find that OC differentiation is enhanced in the absence of p100 in vitro. These results demonstrate that stimulated osteoclastogenesis is regulated by a
pathway involving RANKL, NIK, and p100.

Materials and Methods
Mice. NIK/ mice were generated by homologous recombination as described (18) on a 129Sv/Ev background. Mice were
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maintained by heterozygote matings in a specific pathogen-free
facility.
Osteoclast Culture. For whole marrow culture, unfractionated
bone marrow cells were cultured in the presence of 1,25 dihydroxyvitamin D3 (2.5  108 M) to induce osteoclast differentiation
(20). After 8 d, cultures were fixed and stained for tartrate-resistant acid phosphatase (TRAP), a marker of OC differentiation,
according to manufacturer’s instructions (Sigma-Aldrich). To obtain bone marrow–derived macrophages (M), marrow cells
were on Petri dishes in the presence of CMG14–12 supernatant
containing the equivalent of 100 ng/ml recombinant M-CSF (21)
for at least 5 d. Equal numbers of WT and NIK/ Ms were replated onto tissue culture plates in the presence of partially purified M-CSF (see M-CSF Preparation) equivalent to 20 ng/ml recombinant M-CSF and the indicated dose of GST-RANKL for
6 d and then fixed and stained for TRAP activity. For analysis of
resorptive activity, Ms were replated onto multiwell Osteologic
slides (BD Biosciences), which are coated with inorganic hydroxyapatite matrix, in the presence of M-CSF and 150 ng/ml
GST-RANKL. After 6 d, cells were fixed in neutral buffered formalin and stained with methylene blue.
In Vivo RANKL Treatment. GST-RANKL was prepared as
described (22). WT and NIK/ mice (2–3 mo old) were injected subcutaneously with GST-RANKL (500 g per day for
7 d) or PBS (sham). Calvaria were fixed overnight in 10% buffered formalin, decalcified in 14% EDTA, embedded in paraffin,
sectioned, and stained for TRAP with a hematoxylin counterstain. The number of OC per 10 fields (100 magnification) for
five mice in each group was counted. Statistics were performed
with the unpaired Student’s t test.
Antibodies. mAbs to RelA and the NH2 terminus of NF-B2
common to p100 and p52 were from Santa Cruz Biotechnology,
Inc., as were the polyclonal antiserum directed against IB and
RelB and the agarose conjugated anti-RelA polyclonal antibody
used for immunoprecipitation.
Semiquantitative RT-PCR. Total RNA was extracted using
RNeasy (QIAGEN), and snf cDNA was generated with AMVRT (Fisher Scientific) according to manufacturers’ instructions
using 1 g total RNA and oligo-dT primers diluted to a final
volume of 100 l. Oligonucleotide primers used for PCR were:
nfkb2 sense, 5-TGGCTGGTGGGGACTTGG-3; nfkb2 antisense, 5-ACCCACCGAGATGTGGGC-3; GAPDH sense,
5-ACTTTGTCAAGCTCATTTCC-3; GAPDH antisense,
5-TGCAGCGAACTTTATTGATG-3; calcitonin receptor
(CTR) sense 5-CATTCCTGTACTTGGTTGGC-3; CTR
antisense, 5-AGCAATCGACAAGGAGTGAC-3; matrix
metaloproteinase 9 (MMP9) sense, 5-CCTGTGTGTTCCCGTTCATCT-3; MMP9 antisense, 5-CGCTGGAAT3 integrin sense, 5-TTACCCGATCTAAGCCCA-3;
CGTGGACATCTACTA-3; and 3 integrin antisense, 5AGTCTTCCATCCAGGGCAATA-3. For each reaction, 1–2
l cDNA was used for the following PCR cycle numbers: nfkb224; GAPDH-24; CTR-34; MMP9-24; and 3 integrin-30.
M-CSF Preparation. Supernatant was harvested from
CMG14–12 cells grown in phenol red–free media, diluted into
triethanolamine buffer, and loaded onto a Q sepharose FastFlow column (Amerhsam Biosciences). M-CSF was eluted first
with a NaCl gradient (0–1.0 M), and then eluted from a second
Q column by pH gradient (pH 7 to 4). Peak fractions were dialyzed against PBS and sterile filtered. Bioactivity was compared with recombinant murine M-CSF (R&D Systems) by assaying proliferation of M-NFS-60, an M-CSF–dependent cell
line (21).
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Subcellular Fractionation. Cells were harvested by treatment
with 10 mM EDTA in PBS for 15–30 min at 4 C followed by
scraping. Nuclear and cytoplasmic fractions were isolated using
the NuCLEAR kit (Sigma-Aldrich). Extracts were quantitated by
a modified Coomassie method (Pierce Chemical Co.). For immunoblots, 5 g of nuclear extract or 25 g of cytoplasmic extract was used, and equivalent loading was verified by Ponceau
red staining after transfer to PVDF membrane.
NF-B DNA Binding Assays. For electrophoretic mobility
shift assay (EMSA), nuclear extracts (2 g) were incubated
with labeled double stranded B3 oligonucleotide (5-AAACAGGGGGCTTTCCCTCCTC-3) at 4 C for 32P-labeled
probes (see Figs. 4 and 5) or at room temperature for biotinlabeled probes (see Fig. 8). Protein–DNA complexes were resolved on nondenaturing 4–20% polyacrylamide gels (Invitrogen) in 0.5  TBE. Radiolabeled gels were dried and subjected
to autoradiography. For nonradioactive detection, the LightShift
chemiluminescent system (Pierce Chemical Co.) was used, according to manufacturer’s instructions, using a biotinylated version of the same oligo (Invitrogen). For RelA supershift, 2 g
polyclonal anti-RelA (Santa Cruz Biotechnology, Inc.) was
added after formation of DNA–protein complexes at room temperature for 15 min. An ELISA-based NF-B assay, the EZDetect p65 ELISA (Pierce Chemical Co.) was performed according
to manufacturer instructions, using 2 g nuclear extract per well,
performed in triplicate. Background (extraction buffer alone, averaged for three wells) was subtracted from each sample. In this
assay, nuclear extract is applied to wells precoated with specific
NF-B oligos followed by anti-p65 (RelA) antibody and an
HRP-conjugated secondary. The assay is developed with chemiluminescent substrates and read on a luminometer/plate reader
(SpectraFluor Plus; Tecan).
Retroviral Transduction. M were transduced with retrovirus
containing vector alone (pMX-puro) (23) or a noncleavable form
of p100 (pMX-p100 GRR) for 24 h in the presence of
CMG14–12 supernatant equivalent to 200 ng/ml rM-CSF and 4
g/ml polybrene (Sigma-Aldrich) and then selected with puromycin for 3 d. Surviving M were passaged on Petri dishes and
grown in M-CSF overnight before the preparation of nuclear extracts, or passaged into 96-well plates, cultured in M-CSF (20 ng/
ml) and GST-RANKL (150 ng/ml) for 5 d, and then fixed and
stained for TRAP activity.

Results
Stimulated Osteoclastogenesis Is Blunted in NIK/ Mice.
To determine if p100 processing has a role in OC differentiation, we placed NIK/ (18) bone marrow cells in osteoclastogenic conditions and found they fail to generate
multinucleated cells expressing TRAP, a marker of the OC
phenotype (Fig. 1 A). In these whole marrow cultures,
stromal cells provide the M-CSF and RANKL required for
osteoclastogenesis. OCs can also be generated in vitro from
pure populations of Ms treated with soluble recombinant
M-CSF and RANKL. As shown in Fig. 1 B, WT Ms exposed to these cytokines form confluent sheets of large,
spread OCs and exhibit exuberant resorptive activity (Fig.
1 C). In contrast, NIK/ cultures, although rich in Ms,
contain only rare, poorly spread TRAP-positive cells (Fig.
1 B) with no detectable resorptive capacity (Fig. 1 C). The
lack of osteoclastogenesis in NIK/ cultures cannot be
773

Novack et al.

Figure 1. NIK/ mice have defective RANKL-mediated osteoclastogenesis in vitro. (A) Equal numbers of WT and NIK/ cells from
unfractionated bone marrow were cultured for 8 d in the presence of
vitamin D3 and then fixed and stained for TRAP, a marker of OC differentiation. Under these conditions, both stromal cells and OC precursors
are present. NIK/ cultures fail to form large, spread, TRAP-positive
OCs. Bar, 300 m. (B) Equal numbers of Ms (expanded from bone
marrow in high doses of M-CSF) from WT and NIK/ mice were
cultured in the presence of M-CSF and the indicated dose of RANKL
for 6 d and then fixed and stained for TRAP. Very few, poorly spread
TRAP-positive cells are seen in the NIK/ cultures. Bar, 100 m. (C) Osteoclastogenic cultures were generated as in B on an artificial hydroxyapatite matrix (Osteologic slides). On day 6, cultures were stained with
methylene blue at basic pH. Resorbed matrix is seen as a clear white
area around dark cells. NIK/ cultures have negligible matrix resorption. Bar, 300 m. (D) WT and NIK/ Ms were treated with
RANKL for 0–4 d and then harvested for RNA extraction. Semiquantitative RT-PCR was performed for CTR, MMP9, and 3 integrin, all
markers of OC differentiation, with GAPDH as control. Although 3
integrin levels are comparable at day 1, all three markers show a failure
in induction from days 2–4 in NIK/ cultures, confirming the morphological lack of differentiation.
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Figure 2. NIK/ mice have normal basal osteoclastogenesis and a
blunted response to RANKL in vivo. (A) TRAP-stained sections of
femurs from unmanipulated 3–4-mo-old WT and NIK/ mice show
no difference in trabecular architecture or OC number red-stained
cells. Bar, 600 m. (B) WT and NIK/ mice were injected with 500
g GST-RANKL or PBS daily for 7 d and killed on the 8th day.
TRAP-stained coronal sections of calvaria adjacent to the sagittal suture
show a dramatic increase in OCs along sutures and sinusoids only in
WT RANKL-treated animals. Bar, 150 m. (C) Quantitation of osteoclasts along inner (sinusoidal) calvarial surfaces for animals described in
B confirms the significant difference in the response of WT and NIK/
mice to RANKL injection. Error bars indicate SEM. *P
0.0001
compared with WT sham. **P 0.001 compared with NIK/ sham
and WT RANKL.

rescued by increasing RANKL by amounts up to 10-fold
the optimal dose for WT cultures (Fig. 1 B, 1,000 ng/ml
RANKL) or by doubling the time in culture (unpublished
data). Given that these experiments were performed using
only Ms, the osteoclastogenic defect in NIK/ whole
marrow cultures resides in OC precursors and not in cytokine-producing stromal cells. The lack of morphological
changes in NIK/ cultures is accompanied by a failure,
beyond day 1, to up-regulate transcripts characteristic of
OCs, including 3 integrin, matrix metalloproteinase 9,
and CTR (Fig. 1 D). However, NIK/ cultures are not
completely unresponsive to RANKL. At day 1, 3 integrin
mRNA is induced in NIK/ cultures at levels similar to
WT. Additionally, NIK/ Ms show normal MAPK activation (unpublished data).
Interestingly, in vivo basal osteoclastogenesis is unaltered
in NIK/ mice. Femurs of unmanipulated 3–4-mo-old
WT and NIK/ mice have similar cortical thickness, trabecular size and distribution, and number of osteoclasts (Fig.
2 A). On the other hand, and consistent with our in vitro
observations, these mutants exhibit a blunted response to osteoclastogenic stimuli. Whereas WT mice generate a robust
sevenfold increase in OC number along calvarial sinuses after 1 wk of RANKL treatment, NIK/ mice show only a
twofold rise (Fig. 2, B and C). Similarly, NIK/ mice fail
to show a significant osteoclastogenic response to a 3-d
course of parathyroid hormone injection (unpublished data).
774

RANKL Induces Processing of p100 in WT but not NIK/,
OC Precursors. Because NIK has been shown to control
p100 processing in response to other TNF family cytokines, we next assessed the effect of RANKL on p100 and
p52 levels in WT and NIK/ cultures. In unstimulated
WT Ms (Fig. 3 A, 0 h), p100 but not p52 is readily detected. Exposure to RANKL yields accumulation of p52
beginning at 4 h, with no change in p100 levels. In contrast, RANKL exposure for as long as 48 h fails to induce
the appearance of p52 in NIK/ OC precursors. Moreover, whereas basal p100 levels are comparable in WT and
NIK/ Ms (0 h for WT and NIK/ in Fig. 3 A), p100
is substantially enhanced (2.5–4-fold) in mutant cells by 8 h
of RANKL exposure, and this increase persists for at least
48 h This effect is specific for RANKL, since exposure of
WT M to TNF does not induce production of p52, although it does increase p100 levels (Fig. 3 B).
Because the nfkb2 gene is itself regulated by NF-B (24),
we asked if increased transcription contributes to the accumulation of p100 in NIK-deficient cells. Semiquantitative
RT-PCR shows that RANKL treatment up-regulates
nfkb2 mRNA fourfold by 6 h in both WT and NIK/
M cultures (Fig. 3 C). Interestingly, nfkb2 mRNA levels
are substantially lower in NIK/ cells at 24 and 48 h. Because NF-B transactivates the nfkb2 gene, this observation
is consistent with a possible decrease in NF-B signaling at
these later times.
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Figure 4. NF-B signaling in NIK/ Ms is intact. (A) Ms were
acutely stimulated with RANKL for the indicated times, and cytoplasmic
(top) and nuclear (bottom) fractions were analyzed by immunoblot for
IB and RelA, respectively. (B) NF-B DNA binding activity was assessed at 0 and 15 min by EMSA using a B3 oligonucleotide probe and
nuclear extracts from A. NF-B signaling is comparable in WT and
NIK/ M cultures in response to RANKL.

Figure 3. RANKL-induced p100 processing does not occur in NIK/
OC precursors despite normal induction of nfkb2 transcription. (A) WT
and NIK/ Ms were treated with RANKL for increasing times, and
total lysates were analyzed by immunoblot to detect changes in p100 and
p52 levels, using a monoclonal antibody recognizing the NH2 terminus
common to p100 and p52. The blot was stripped and reprobed with antiactin as a loading control (bottom). In WT cultures, p100 levels remain
steady, whereas p52 levels are increased by RANKL treatment. Parallel
NIK/ cultures fail to generate p52 at any time point and accumulate
p100. (B) WT Ms were treated with RANKL or TNF for the indicated times, and p100/p52 levels were assessed by immunoblot as in A.
p100 processing does not occur in response to TNF. (C) WT and
NIK/ Ms were treated with RANKL for increasing times, and RNA
was harvested. Levels of nfkb2 mRNA were analyzed by semiquantitative
RT-PCR using GAPDH as a control. Numbers beneath lanes indicate
fold increase over WT 0 h baseline. Although WT and NIK/ cultures
show equivalent induction of nfkb2 at 6–12 h, levels are significantly
lower in NIK/ cultures thereafter.

NF-B Signaling Is Intact in NIK/ Ms but Blunted in
NIK/ preOCs. To determine whether the differences in
p100 processing between WT and NIK/ cultures impacts
NF-B signaling, we assessed NF-B activation in Ms
(time 0 in Fig. 3 A in which WT and NIK/ cultures have
equivalent p100 levels) and preOCs (48 h in Fig. 3 A in
which NIK/ cultures have more p100 and no p52). Acute
stimulation of Ms with RANKL led to normal degradation of IB, nuclear translocation of RelA, NF-B DNA
binding activity, and resynthesis of IB (an NF-B–
dependent event) in NIK/ M cultures (Fig. 4, A and B)
consistent with the findings of Yin et al. (18). In contrast,
RANKL stimulation of preOCs (generated by exposing
Ms to RANKL for 48 h, then starving of serum and cytokines for 3 h) has very different results in WT and NIK/
cultures. Similar to its effects in Ms (Fig. 4), RANKL
stimulation of WT preOCs leads to IB degradation, nuclear translocation of RelA, and increased NF-B DNA
775
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binding capacity (Fig. 5, A–C). NIK/ preOCs degrade
IB in a manner similar to that of WT cells (Fig. 5 A), although basal levels are a bit lower than WT. On the other
hand, RelA does not appear in nuclear extracts of the mutant cells (Fig. 5 A). Concordantly, both basal and stimulated NF-B DNA binding activity is decreased as assessed
by EMSA (Fig. 5 B) and an ELISA-based chemiluminescent assay for RelA-specific NF-B activation (Fig. 5 C).
In addition, resynthesis of IB is blunted in the absence of
NIK (Fig. 5 A, 60 min).
To determine if the nuclear translocation of other NFB subunits is affected in NIK/ cultures, we analyzed
nuclear extracts of WT and NIK/ Ms and preOCs by
immunoblot (Fig. 6). As expected based on Fig. 3 A,
within 60 min of RANKL stimulation, neither WT nor
NIK/ Ms have nuclear p52. Only WT preOCs contain
nuclear p52, and this is only slightly responsive to RANKL
stimulation. Additionally, RelB is present at high levels in
WT preOCs, at very low levels in WT Ms, and absent in
NIK/ Ms and preOCs.
These data indicate that, as in other cytokine signaling
pathways, NIK is not involved in the degradation of IB
in response to RANKL. NIK does, however, play a permissive role in NF-B nuclear translocation in committed
preOCs, suggesting increased activity of another IB-like
protein in NIK-deficient preOCs but not M.
p100 Functions as an IB Protein in NIK/ preOCs. To
determine if the enhanced p100 appearing in RANKLtreated NIK/ preOCs functions as an IB, RelA was immunoprecipitated from resting or RANKL-stimulated preOCs, and its association with p100 and IB was assessed
by immunoblot (Fig. 7). As expected, RelA levels are similar in WT and NIK/ cells, and association of the subunit
with IB is decreased by RANKL treatment in both circumstances. On the other hand, although p100 does not
associate with RelA in WT cells, it is readily detected in
resting NIK/ RelA immunoprecipitates, and this association increases in response to RANKL. These data suggest
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Figure 5. NF-B does not accumulate in the nucleus of NIK/ preOCs.
(A) PreOCs, generated by treating Ms with RANKL for 48 h followed
by a 3 h starvation, were stimulated with RANKL for the indicated times,
and cytoplasmic (top) and nuclear (bottom) fractions were isolated and
analyzed by immunoblot for IB and RelA, respectively. Although
IB gets degraded in both WT and NIK/ cultures, RelA does not
accumulate in the nucleus in the absence of NIK. (B) Nuclear extracts
prepared as in A were analyzed for NF-B DNA binding activity by
EMSA. Whereas WT preOC cultures have detectable NF-B activity at
baseline and further induction by RANKL, NIK/ preOC cultures
show little binding activity with or without RANKL. (C) RelA-specific
NF-B DNA binding activity was assessed by ELISA (EZ Detect kit;
Pierce Chemical Co.) using the same preOC nuclear extracts as in A. In
this assay, NF-B–specific oligos are bound to a plate. Nuclear extract is
then applied followed by anti-p65 (RelA) antibody and an HRP-conjugated
secondary. The assay is developed with chemiluminescent reagents and
read on a luminometer/plate reader. Each sample was run in triplicate.
Unmutated (UnMu) and mutant (Mu) soluble oligos were added to the
WT 30-min sample to confirm specificity. The results of this assay mirror
the EMSA in B and confirm lower baseline NF-B activity and lack of
RANKL-mediated induction in NIK/ preOCs. Binding activity is
abolished by addition of the unmutated oligo and unaffected by the mutant
oligo (last two bars).

that, in NIK/ OC precursors, exposure to RANKL results in accumulation of p100 because it cannot be processed to p52. Accumulated p100 would then bind NF-B
subunits as they are released from IB, preventing their
nuclear translocation and the subsequent induction of gene
transcription. This model predicts that expression of a nonprocessable form of p100 in WT OC precursors would inhibit osteoclastogenesis.
To test this hypothesis, we used a p100 construct,
p100 GRR, which lacks the glycine-rich region determining the site of proteosomal cleavage and hence cannot
be processed to p52 (5). Using the pMX-puro retroviral
vector (23), we expressed p100 GRR or vector alone as a
control in WT Ms (Fig. 8 A). Cells transduced with pMX
or pMX-p100 GRR were stimulated with RANKL for
15 min, and NF-B DNA binding activity was assessed by
776

EMSA compared with unstimulated controls. Expression of
p100 GRR markedly inhibits induction of NF-B activity (Fig. 8 B). Transduced Ms were also cultured in osteoclastogenic concentrations of RANKL plus M-CSF.
Consistent with the role of unprocessed p100 as an NF-B
inhibitory protein, expression of p100 GRR inhibits formation of mature OCs (Fig. 8 C).
Finally, if, as we propose, p100 blunts RANKL-stimulated osteoclastogenesis, OC precursors lacking p100 should
show enhanced sensitivity to RANKL. In fact, nfkb2/
Ms (which lack both p100 and p52) form OCs at lower
doses of RANKL and with shorter exposure to the cytokine compared with WT controls (Fig. 9). These data confirm that the nfkb2 gene product p100 has an inhibitory
effect on RANKL-stimulated osteoclastogenesis, although
p52, which potentially contributes to total NF-B signaling, is dispensable.

Discussion
OCs are uniquely capable of degrading both the organic
and inorganic components of bone, and in concert with
bone-building osteoblasts are required for maintenance of
skeletal integrity and mineral homeostasis (1). Stimulated
OC recruitment prompts the skeletal lesions of postmenopausal osteoporosis, rheumatoid arthritis, and osteolytic
metastasis of malignant tumors. Unlike the mesenchymeFigure 7. Association of RelA
and p100 is increased in NIK/
preOCs. PreOCs (generated as
in Fig. 5) were starved for 3 h
and restimulated with RANKL
for the indicated times before lysis.
Total lysates were immunoprecipitated with anti-RelA antibody and analyzed by immunoblot
for p100, RelA, and IB. In both WT and NIK/cultures, association
of RelA and IB were reduced upon RANKL treatment. In WT cells,
RelA associates with p100 only transiently. In contrast, RelA is bound to
p100 in NIK/ cultures before addition of RANKL, and this association
is increased with RANKL treatment as IB is degraded.
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Figure 6. RelB and p52 fail to accumulate in the nucleus in NIK/
preOCs. Immunoblot of nuclear extracts from M and preOC cultures
treated acutely with RANKL shows accumulation of p52 only in WT
preOCs (top). Levels of nuclear RelB are highest in WT preOCs, with
minimal acute induction by RANKL. WT Ms show low levels of nuclear
RelB, whereas NIK/ Ms and preOCs lack this NF-B subunit. A
background band (bkgd) in RelB immunoblots shows equivalent signal in
all lanes.

Figure 8. Expression of a noncleavable form of p100 in WT Ms
inhibits NF-B signaling and osteoclastogenesis. (A) WT Ms were
transduced with retrovirus bearing empty pMX or pMX-p100 GRR, a
noncleavable form of p100, overnight and selected in puromycin for 3 d
before lysis. Immunoblots for p100/p52 demonstrate expression of the
retroviral driven p100 GRR (lane 2) at levels three to fourfold above
endogenous p100 (lane 1), similar to that seen in RANKL-treated NIK/
Ms. (B) NF-B activity was assessed by EMSA on Ms transduced with
pMX (control) or pMX-p100 GRR as above. Lanes 1–2, cells transduced with pMX, unstimulated (lane 1), or treated with RANKL for 15
min (lane2); lanes 3–4, cells transduced with pMX-p100 GRR, unstimulated (lane 3), or treated with RANKL for 15 min (lane 4); lane 5,
RANKL-stimulated vector control, with unlabeled probe at 50-fold excess; and lane 6, RANKL-stimulated vector control supershifted with
polyclonal anti-RelA antibody. The supershifted band is indicated (ss).
Expression of p100 GRR in Ms dramatically decreases NF-B signaling by RelA in response to RANKL. (C) After the 3 d puromycin selection,
retrovirally transduced Ms were cultured in RANKL for 5 d and then
stained for TRAP. Expression of p100 GRR inhibits osteoclastogenesis
in these WT cultures. Bar, 300 m.

derived osteoblasts that survive for several months, bone
marrow–derived OCs are short-lived with a lifespan of 1–2
wk (25). Therefore, tight control of OC differentiation is as
critical as control of OC activity for skeletal homeostasis.
NF-B is potently induced by RANKL in OC precursors
(26), and the occurrence of osteopetrosis, with an early
block in osteoclastogenesis, in nfkb1/nfkb2 double knockout
mice established the importance of this signal (19, 27). Individual ablation of either nfkb1 or nfkb2 does not impact the
skeleton of unmanipulated mice, indicating mutual compensation between p50 and p52. In vitro osteoclastogenesis, by
coculture with osteoblasts, is also not impaired in either
nfkb1- or nfkb2-deficient mice (19). nfkb1/ and nfkb2/
mice lack both the precursor (p105 or p100) and the active
NF-B subunit (p50 or p52). Due to the potential opposing
functions of the precursors (as IBs) and the products (as active NF-Bs), loss of both precursor and product may mask
the function of either one. Thus, the impact of individual
subunits on specific NF-B targets, or on a physiological
process such as osteoclastogenesis, is unresolved.
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Figure 9. RANKL-mediated osteoclastogenesis in vitro is enhanced in
the absence of p100. Ms from WT (A) and nfkb2/ (B) mice were cultured with increasing doses of GST-RANKL for 3, 4, or 5 d and then
fixed and stained for TRAP. The number of mature OCs was counted
for one 4 field per well, 4 wells per condition. At high doses of
RANKL (50–150 ng/ml), WT OCs begin to form on day 4 and are confluent on day 5. In contrast, nfkb2/ OCs begin to form on day 3 with
as little as 25 ng/ml RANKL and are confluent on day 4. The peak numbers of OCs are slightly lower for nfkb2/ cultures than for WT cultures
because the nfkb2/ OCs are larger. This is also the case for the nfkb2/
cultures at 25 ng/ml RANKL on day 5 in which the OCs are smaller
than at the higher doses. Thus, nfkb2/ cultures, which lack both p100
and p52, show accelerated osteoclastogenesis at lower doses of RANKL
compared with WT controls.

The conversion of p105 to p50 is predominantly constitutive, and no specific regulators of the process are in hand
(4). In contrast, processing of p100 to p52 is tightly controlled by a known signaling pathway involving NIK (9,
10). Therefore, by manipulating this pathway it is possible
to substantially alter the ratios of these two proteins. For instance, in the absence of processing, increased transcription
of the nfkb2 gene can enhance p100 levels. When both
synthesis and processing of p100 are stimulated, p52 levels
rise while p100 levels remain stable, greatly increasing the
ratio of p52 to p100. We have used the NIK/ system in
which p100 accumulates due to an absence of processing
and have uncovered a requirement for the processing of
p100 for RANKL-stimulated osteoclastogenesis.
NIK directly interacts with TRAFs (28), a family of
adaptors that mediate NF-B and JNK activation downstream of TNF receptor family members, including
RANK, CD40, and Lt R. Although overexpression studies suggested that NIK is the kinase bridging this receptor/
adaptor family and the classical NF-B cascade (via its direct interaction with IKKs) (29), this role is not supported
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by data from the alymphoplasia and NIK/ mice, which
do not exhibit a global defect in NF-B signaling (14, 18,
30). Furthermore, NIK, which binds to and activates
IKK, is specifically required for the processing of p100 to
p52 (9). The similar defects in NIK-, IKK-, and nfkb2deficient mice indicate that the p100 to p52 pathway is
critical for B cell maturation (10–12, 16, 18). BAFF, a TNF
family member, has been shown recently to activate this
pathway in B cells (31).
In the OC lineage, we find that p100 processing is initiated by RANKL and promotes osteoclastogenesis. Other
RANKL-mediated signaling events, including activation of
JNK and ERK and degradation of IB, occur within
5–15 min of cytokine–receptor interactions (32). NIK, IKK,
and p100 are all present in unstimulated OC precursors,

but p100 processing is not detectable before 4–6 h after exposure to RANKL. Blockade of protein translation with
cyclohexamide also prevents p100 processing (33, 34 and
unpublished data). It is therefore likely that several intermediary events, including protein translation, occur between RANK activation and NIK-mediated p52 expression, leading to a several hour delay.
We and others find that induction of p100 processing is
restricted to a subset of TNF family cytokines, including
RANKL, BAFF, and CD40L but not TNF or IL-1 (31,
33, 34 and this article). Although TNF can synergize
with RANKL to enhance osteoclastogenesis when added
after 48 h or RANKL exposure, it inhibits OC differentiation if added simultaneously (35). The TNF-mediated
increase in p100 levels, without generation of p52, seen in
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Figure 10. Model for p100-mediated blockade
of NF-B signaling in NIK-deficient preOCs. See
Discussion.
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M (Fig. 3 B) may explain the initial inhibitory effect of
TNF at early stages of osteoclastogenesis. The clear stimulatory effect of TNF on OCs in vivo is not easily explained. However, other factors present in inflammatory
conditions may counteract the p100 effect, allowing the
many signals common to TNF and RANKL, such as activation of the classical NF-B pathway, MAPKs, and
PI3K, to act unopposed.
The features of the NIK/IKK/p100 pathway in the
OC lineage distinguish it from all previous descriptions of
the NF-B pathway. We propose (Fig. 10) that RANKL
induces degradation of IB, releasing NF-B, predominantly as RelA/p50 dimers, to rapidly accumulate in the
nucleus. After several hours, RANKL also stimulates NIK
to process p100, thus releasing p52, which can then complex with RelA or with RelB and travel to the nucleus (36,
37). This transcriptionally active pool of nuclear NF-B
stimulates osteoclastogenesis. In the absence of NIK, NFB signaling in OC precursors is initially intact. However,
after 1–2 d of RANKL stimulation sufficient p100 accumulates in the cytosol to bind RelA/p50 dimers as they are
released from IB. This cytoplasmic retention of NF-B
combined with the lack of p52 reduces NF-B–mediated
transcription in the nucleus and inhibits osteoclastogenesis.
In vitro, the defect in RANKL-mediated osteoclastogenesis in NIK/ cultures is profound. In vivo, NIK-deficient mice are resistant to stimulated osteoclastogenesis in
response to injection of RANKL or parathyroid hormone
but show no bone phenotype in the basal state. Alymphoplasia mice, like NIK/ mice, have normal bone architecture and a striking defect in osteoclastogenesis in vitro (unpublished data). Mice lacking p100 (nfkb2/) also show no
basal bone phenotype, despite a pronounced enhancement
of RANKL-mediated osteoclastogenesis in vitro. Two
general possibilities present themselves to explain the apparent paradox in the in vivo and in vitro phenotypes.
First, culture conditions may mirror stimulated but not
basal osteoclastogenesis. Second, because of compensatory
mechanisms operating in vivo, many knockout mice exhibit no phenotype until stressed. As regards to the present
situation, although M-CSF and RANKL are necessary for
osteoclastogenesis in vivo and sufficient for differentiation
of pure OC precursors in vitro, other cytokines modulate
osteoclastogenesis within the bone microenvironment. For
example, TNF, in the context of permissive levels of
RANKL, enhances osteoclastogenesis in many inflammatory conditions (35, 38–40) and also supports a normal
level of basal osteoclastogenesis via the p55 TNF receptor
(41). TGF can also support RANKL-mediated osteoclastogenesis (42, 43). In fact, a combination of RANKL,
TNF, and TGF rescues the NIK/ defect in osteoclastogenesis in vitro (unpublished data). We suspect that the
presence of these factors, and perhaps others in the bone
microenvironment, allows OC differentiation to occur at a
normal basal rate in NIK/ mice but cannot compensate
for the inhibitory influence of accumulated p100 induced
by exogenous RANKL or PTH, which exerts its osteoclastogenic effect through RANKL.
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Our studies uncover a novel NF-B pathway using
RANKL-induced processing of p100 to control the pool of
inhibitory IB proteins. Whereas p100 processing is also
regulated in B cells by NIK, it is increased p52 and not decreased p100 that is critical for B cell maturation (10, 17).
Interestingly, p52 itself is dispensable for osteoclastogenesis,
since the nfkb2-deficient mouse, which lacks both p100
and p52, has normal OC numbers in vivo (19) and increased OC numbers in vitro (Fig. 9). In addition, regulation of NF-B signaling by p100 is distinct from the
classical IB pathway in both kinetics (hours versus minutes) and upstream regulation (IKK complex versus NIK/
IKK). Thus, these two distinct mechanisms for NF-B
control (IB degradation and p100 processing) allow for
cell type and receptor-specific responses within the NF-B
pathway.
NIK/ osteoclastogenesis in vivo is not impaired in the
basal state but only in conditions of excess RANKL such as
accompanies administration of PTH. This observation leads
us to propose that the modulating effect of NIK/p100 on
osteoclastogenesis is important in clinical conditions of increased osteoclastogenesis, such as osteoporosis, rheumatoid
arthritis, and osteolytic bone metastasis, in which RANKL
expression is enhanced. Most importantly, the fact that
p100 arrests stimulated osteoclastogenesis makes it a potential therapeutic target in diseases of accelerated bone loss.
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